ANL
Adlai Nortye (ANL)
$46
About Adlai Nortye (ANL)
Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company, which engages in the provision of development of cancer therapies for patients with stages of tumors. It offers AN0025, a clinical stage, potential EP4 antagonist designed to modulate tumor microenvironment. The company was founded on May 9, 2018, and is headquartered in Hangzhou, China.
Details
Daily high
$11.34
Daily low
$10.12
Price at open
$10.12
52 Week High
$17.25
52 Week Low
$0.88
Market cap
357.1M
Dividend yield
0.00%
Volume
46,570
Avg. volume
117,292
P/E ratio
-10.34
Adlai Nortye News
Details
Daily high
$11.34
Daily low
$10.12
Price at open
$10.12
52 Week High
$17.25
52 Week Low
$0.88
Market cap
357.1M
Dividend yield
0.00%
Volume
46,570
Avg. volume
117,292
P/E ratio
-10.34